CABA · Cabaletta Bio, Inc.

Cabaletta Bio Inc Is A Late Clinical-Stage Biotechnology Company Focused On The Discovery And Development Of Engineered T Cell Therapies For Autoimmune Diseases. Its Proprietary Cabaletta Approach To B Cell Ablation (Caba) Platform Includes The Carta Approach, Which Uses Chimeric Antigen Receptor T Cells To Eliminate B Cells And Potentially Reset The Immune System. The Company Develops Cellular Therapies Including Car T And Caar T Product Candidates. Its Candidate, Rese-Cel (Resecabtagene Autoleucel), A Cd19-Car T Cell Therapy, Is Being Evaluated In Phase 1/2 Trials For Autoimmune Diseases Such As Systemic Lupus Erythematosus, Myositis, Systemic Sclerosis, Generalized Myasthenia Gravis, And Pemphigus Vulgaris.